Author:
Mandeville Kate L.,Valentic Maja,Ivankovic Damir,Pristas Ivan,Long Jae,Patrick Hannah E.
Abstract
Objectives:The aim of this study was to identify guidelines and assessment tools used by health technology agencies for quality assurance of registries and investigate the current use of registry data by HTA organizations worldwide.Methods:As part of a European Network for Health Technology Assessment Joint Action work package, we undertook a literature search and sent a questionnaire to all partner organizations on the work package and all organizations listed in the International Society for Pharmaco-economics and Outcomes Research directory.Results:We identified thirteen relevant documents relating to quality assurance of registries. We received fifty-five responses from organizations representing twenty-one different countries, a response rate of 40.5 percent (43/110). Many agencies, particularly in Europe, are already drawing on a range of registries to provide data for their HTA. Less than half, however, use criteria or standards to assess the quality of registry data. Nearly all criteria or standards in use have been internally defined by organizations rather than referring to those produced by an external body. A comparison of internal and external standards identified consistency in several quality dimensions, which can be used as a starting point for the development of a standardized tool.Conclusion:The use of registry data is more prevalent than expected, strengthening the need for a standardized registry quality assessment tool. A user-friendly tool developed in conjunction with stakeholders will support the consistent application of approved quality standards, and reassure critics who have traditionally considered registry data to be unreliable.
Publisher
Cambridge University Press (CUP)
Reference21 articles.
1. Stark, N (CDG Whitepapers). Registry studies: Why and how. http://clinicaldevice.typepad.com/cdg_whitepapers/2011/07/registry-studies-why-and-how.html. (accessed December 6, 2017).
2. The GRACE Checklist for Rating the Quality of Observational Studies of Comparative Effectiveness: A Tale of Hope and Caution
3. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
4. Posada, M , del Otero, L , Villaverde, A , Data quality, validation and data source integration in rare disease registries. WP 7 deliverable EPIRARE project. 2014. http://www.epirare.eu/_down/del/D4_GuidelinesfordatasourcesandqualityforRDRegistriesinEurope.pdf (accessed December 6, 2017).
5. Commentary: We still need observational studies of drugs—they just need to be better
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献